Elsevier

Schizophrenia Research

Volume 193, March 2018, Pages 263-268
Schizophrenia Research

Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

https://doi.org/10.1016/j.schres.2017.06.059Get rights and content

Abstract

Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30 months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.

Introduction

Schizophrenia is, by any estimate, a disorder of major public health significance. Although treatment options for this disabling condition have increased (and improved) over time, it is sobering that schizophrenia is still characterized by persistent functional impairment and recurrent psychotic relapses for most/many patients. Wyatt (1991) proposed that relapse in schizophrenia was a biologically toxic event, leading successively to deteriorations in course of illness and overall functioning. Complementarily, Loebel et al. (1992) showed that each successive relapse among first episode schizophrenia patients was more prolonged than the prior relapse. A longitudinal MRI study of patients with schizophrenia found that relapse was associated with progressive loss of cortical tissue and overall brain volume (Andreasen et al., 2013). Ample and compelling evidence, largely from antipsychotic withdrawal and maintenance studies with a placebo-controlled condition (Gilbert et al., 1995, Kane, 1996, Schooler et al., 1997) shows that patients with schizophrenia have an inordinately high risk of relapse over time if they are not receiving treatment with antipsychotic medications. More recent evidence suggests that second-generation antipsychotic (SGA) medications reduce the risk of relapse when compared to first generation antipsychotics (FGAs) (Leucht et al., 2003). Thus, it is plausible that relapse is more than an expression of worsening psychopathology but may represent some fundamental pathobiological event and/or follow some discrete neurobiological trajectory. However, the underlying neurobiological mechanisms that drive these effects are not clear. We have previously proposed that brain derived neurotrophic factor (BDNF) might be a biological marker underlying a cascade of events in relapse in schizophrenia (Pillai and Buckley, 2012).

There is intense interest in the discovery and application of biomarkers to major mental illnesses (Arnow et al., 2015, Ivleva et al., 2016, Weickert et al., 2013). BDNF plays a critical role in neurodevelopment and neuronal and synaptic plasticity (Lu et al., 2014). A number of preclinical, clinical, as well as imaging studies indicate a potential role of BDNF in the pathophysiology of schizophrenia (Ahmed et al., 2015, Buckley et al., 2011, Harrisberger et al., 2015). For example, post-mortem studies show that schizophrenia patients have lower BDNF mRNA levels in the prefrontal cortex and hippocampus (Reinhart et al., 2015, Thompson Ray et al., 2011, Weickert et al., 2003). Concentrations of BDNF in cord blood from infants exposed to obstetric complications who later developed schizophrenia were lower than in cord blood from exposed infants who did not develop the disorder (Cannon et al., 2008). Serum and plasma BDNF levels in adult schizophrenia patients are generally reduced compared with healthy subjects, including never-medicated, first-episode patients (Buckley et al., 2007, Pillai, 2008, Pandya et al., 2013). In animal experiments, the acquisition and maintenance of spatial memory are impaired when BDNF signaling is decreased (Mizuno et al., 2000a, Mizuno et al., 2000b, Linnarsson et al., 1997); however, brain BDNF is increased when rodents perform a spatial learning task (Mizuno et al., 2000a, Mizuno et al., 2000b) or are housed in cognitively stimulating environments (Ickes et al., 2000). Indeed, Vinogradov et al. (2009) found that schizophrenia subjects who participated in 10 weeks of neuroplasticity-based computerized cognitive training showed a significant increase in serum BDNF compared with carefully matched control subjects. Together, these studies indicate that peripheral BDNF levels may serve as a biomarker for clinical outcomes in schizophrenia subjects.

The PROACTIVE (Preventing Relapse Oral Antipsychotics Compared to Injectables eValuating Efficacy) study was a clinical trial evaluating relapse and clinical outcomes over 30 months in patients who were randomly assigned to receive the long-acting SGA, risperidone microspheres (LAI-R), or oral SGAs. Serial plasma samples collected from the patients enrolled in PROACTIVE were examined to test the hypothesis that a decrease in plasma BDNF levels could predict relapse in schizophrenia. Also, the relationship between plasma BDNF and hospitalization or exacerbation was examined at baseline and follow up visits. Based upon the prevailing findings, albeit from smaller and often cross sectional studies of BDNF, this study was funded by the National Institute of Mental Health (clinicaltrials.gov NCT00330863) as a translational component to the already funded PROACTIVE study to allow a rigorous and longitudinal evaluation of BDNF and relapse in schizophrenia.

Section snippets

Study design and subjects

The study is described in detail in an earlier publication (Buckley et al., 2015) and was approved by Institutional Review Boards at all sites and at the coordinating center. In brief, 305 patients with a DSM IV-TR diagnosis of schizophrenia or schizoaffective disorder were enrolled at eight U.S. academic centers and randomly assigned to receive either LAI-R or physician's choice of oral SGA medication. Following randomization, clinical teams on-site were not blinded to treatment assignment;

Results

We collected a total of 2315 plasma samples from 221 of the 305 study participants. The number of BDNF values (corresponding to the number of visits at which a blood sample was collected for BDNF) obtained per subject ranged from 1 to 23 (median = 11) in the total sample; the numbers were similar in the oral (range 1 to 23, median = 10) and LAI-R (range 1 to 22, median = 12) treatment groups. Table 2 shows the demographic details of the study subjects who had baseline BDNF values.

Discussion

There is intense interest in BDNF in neuroscience and applicability of BDNF measurements as a potential biomarker for mood disorders and schizophrenia in particular. Significant differences in plasma BDNF levels have been found between schizophrenia and control subjects (Buckley et al., 2011). That said, it remains uncertain whether BDNF reflects the underlying illness, trait, or state changes in symptoms of schizophrenia. Moreover, studies on the relationship between antipsychotic treatment

Funding body agreements and policies

The study was supported by funding from National Institute of Health (NIH) (Grant No. U01MH070011-S1)/National Institute of Mental Health (NIMH) to Dr. Buckley (Grant No. U01MH070011).

Contributors

Buckley and Schooler designed the study. Goff, Kopelowicz, Lauriello, Manschreck, Mendelowitz, Miller, Severe, Wilson, Ames, Bustillo and Kane contributed to the subject recruitment and sample collection. Pillai and Peter performed analyses. Looney undertook the statistical analysis. Pillai and Buckley wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

Conflict of interest

All authors declare that they have no financial interests or potential conflicts of interest related directly or indirectly to this work.

Acknowledgements

We are thankful to Mr. Ammar Kutiyanawalla for his help with BDNF analysis.

References (44)

  • V. Reinhart et al.

    Evaluation of TrkB and BDNF transcripts in prefrontal cortex, hippocampus, and striatum from subjects with schizophrenia, bipolar disorder, and major depressive disorder

    Neurobiol. Dis.

    (2015)
  • Y.L. Tan et al.

    Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics

    Neurosci. Lett.

    (2005)
  • S. Vinogradov et al.

    Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia?

    Biol. Psychiatry

    (2009)
  • R. Yoshimura et al.

    Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients

    Prog. Neuro-Psychopharmacol. Biol. Psychiatry

    (2007)
  • N.C. Andreasen et al.

    Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study

    Am. J. Psychiatry

    (2013)
  • B.A. Arnow et al.

    Depression subtypes in predicting antidepressant response: a report from the iSPOT-D trial

    Am. J. Psychiatry

    (2015)
  • P.F. Buckley et al.

    Brain-derived neurotrophic factor: findings in schizophrenia

    Curr. Opin. Psychiatry

    (2011)
  • P.F. Buckley et al.

    Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study

    Schizophr. Bull.

    (2015)
  • S.L. Chen et al.

    Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan

    J. NeuroImmune Pharmacol.

    (2012)
  • J.G. Csernansky et al.

    A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

    N. Engl. J. Med.

    (2002)
  • P.L. Gilbert et al.

    Neuroleptic withdrawal in schizophrenic patients. A review of the literature

    Arch. Gen. Psychiatry

    (1995)
  • A. González-Pinto et al.

    Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics

    Int. Clin. Psychopharmacol.

    (2010)
  • Cited by (19)

    • The role of BDNF and NGF plasma levels in first-episode schizophrenia: A longitudinal study

      2022, European Neuropsychopharmacology
      Citation Excerpt :

      However, significant correlations were found and replicated between baseline plasma levels of both BDNF and NGF, and symptom severity in the subsequent stages after the first-episode, indicating that neurotrophins, specially BDNF, could be useful biomarkers of the underlying illness trait in clinical remission stages. Our results agree with a recently published study that did not find significant associations between baseline BDNF plasma and subsequent relapse, hospitalization or exacerbation in schizophrenia subjects prospectively evaluated over 30 months (Pillai et al., 2018). Thus, the present study adds to the negative studies within cohorts of patients with schizophrenia in early stages.

    • Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial

      2020, Schizophrenia Research
      Citation Excerpt :

      Schizophrenia is a chronic, frequently recurrent illness as a high proportion of patients experience relapse after improvement, remission or even recovery (Goff et al., 2017). Relapse results in serious consequences, including deterioration in psychosocial and vocational functioning (Pillai et al., 2018), as well as social disruption (Tandon et al., 2010), and puts substantial burden on the patients, families and caregivers (Genduso and Haley, 1997; Kane, 2007). Additionally, relapse increases healthcare costs and potential work force loss (Genduso and Haley, 1997).

    View all citing articles on Scopus
    View full text